Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer: Trends in Pharmacological Sciences
The Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature
Amgen's AMG 510 Targeted Cancer Therapy (NASDAQ:AMGN) | Seeking Alpha
Amgen unveils its KRas inhibitor in human clinical trials
Anti-Tumor Drug AMG 510 Shows Promise in Phase 1 Trial | City of Hope
AMG 510 covalently modifies KRAS(G12C) in tumours and inhibits... | Download Scientific Diagram
Understanding the influence of AMG 510 on the structure of KRASG12C empowered by molecular dynamics simulation - ScienceDirect
AMG 510 combined with cytotoxic or targeted agents results in enhanced... | Download Scientific Diagram
Cancer Drug Discovered with ALS Help Enters Phase 2 Trials - Biosciences Area
Amgen unveils its KRas inhibitor in human clinical trials
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors | Journal of Medicinal Chemistry
![PDF] KRasG12C inhibitors in clinical trials: a short historical perspective† †Electronic supplementary information (ESI) available. See DOI: 10.1039/d0md00096e | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/79175af828886f5f656cc808296d9057e16dceaa/2-Figure1-1.png "PDF] KRasG12C inhibitors in clinical trials: a short historical perspective† †Electronic supplementary information (ESI) available. See DOI: 10.1039/d0md00096e | Semantic Scholar")
PDF] KRasG12C inhibitors in clinical trials: a short historical perspective† †Electronic supplementary information (ESI) available. See DOI: 10.1039/d0md00096e | Semantic Scholar
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity | Nature
Asco 2019 – KRAS chase heats up with Amgen data | Evaluate
AMG 510 inhibits tumour growth of patient-derived xenografts, and... | Download Scientific Diagram
CodeBreak 100: results show durability of clinical benefit with sotorasib in patients with non-small cell lung cancer - Onco Americas
Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes | npj Precision Oncology
The Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature
RSC Medicinal Chemistry
Mixed data: AMG 510 in tumours with KRASG12C - Medical Conferences
Ongoing clinical trials involving direct targeting of KRAS. | Download Scientific Diagram
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity | Nature
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity | Nature
KRAS(G12C)–AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations | Scientific Reports
